What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Rimegepant has shown to reduce monthly migraine days more than placebo in the clinical trial BHV3000-305. However, it has not been directly compared with the main comparators (erenumab, fremanezumab, galcanezumab), and indirect comparisons suggest it may be similar or less effective than these treatments. This indicates comparable efficacy but lacks a clear edge over existing options.
Does the economic case hold at the expected price? — Cost effectiveness
Rimegepant is considered cost-effective compared to two of the three standard treatments, with the committee concluding that it provides a positive incremental net health benefit at acceptable ICER thresholds. This suggests a strong economic value proposition.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that rimegepant may improve quality of life, as it is associated with a reduction in migraine days, which can significantly impact daily functioning. However, the difference in utility values at baseline was not statistically significant, suggesting moderate improvements.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The adverse events associated with rimegepant were reported as mild to moderate, with low rates of severe or serious events. This indicates a very good tolerability profile, supporting its use in the target population.
Was the drug compared against what payers expect? — Comparator Selection
The comparators selected (erenumab, fremanezumab, galcanezumab) are appropriate as they represent the standard of care for patients who have not responded to previous treatments. The committee acknowledged the relevance of these comparators despite the lack of direct evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included adults with episodic migraine, but there are concerns regarding the representativeness of the population due to the exclusion of those with a history of no response to prior treatments. This limits the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Rimegepant is positioned as a fourth-line treatment after other options have failed, which aligns with current clinical practice. The potential for primary care prescription is noted, although specialist involvement is likely required initially.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model suggests that rimegepant could provide resource use cost savings, particularly if prescribed in primary care. However, there are concerns about the accuracy of the cost assumptions used in the model.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes a phase 2/3 trial and a network meta-analysis, but there are limitations regarding the comparability of trials and the lack of direct evidence. This raises concerns about the robustness of the conclusions drawn.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the clinical evidence, particularly related to the NMA and the applicability of the trial population to the broader patient population. This uncertainty may restrict the use of rimegepant in practice.
